Avacincaptad Pegol

Introduction Overview

Generic Name

avacincaptad pegol

Brand Name

Izervay

Dosage Form

intravitreal injection (solution for injection)

Drug Class

Anti-angiogenic ophthalmic agents

Pharmacokinetics

Absorption:
Avacincaptad pegol is administered via intravitreal injection directly into the vitreous humor of the eye, which circumvents systemic absorption routes typical for oral or intravenous medications. This localized delivery ensures high bioavailability within the ocular tissues, particularly the retina and choroid, while minimizing systemic exposure. Pharmacokinetic studies indicate that after intravitreal administration, avacincaptad pegol distributes within the posterior segment of the eye, targeting retinal cells implicated in geographic atrophy progression. The drug absorption into systemic circulation is minimal and occurs slowly through ocular vasculature, reducing systemic side effects.

Distribution:
Following intravitreal injection, avacincaptad pegol concentrates primarily in the vitreous humor and retinal tissues, which are the therapeutic targets for treatment of geographic atrophy secondary to age-related macular degeneration (AMD). Due to its molecular size as an oligonucleotide-based complement inhibitor, it exhibits limited diffusion into the anterior segment, maintaining localized action. Systemic distribution is limited; animal and early human studies demonstrate minimal plasma levels post-injection, reflecting the drug’s confinement within the eye. This localized distribution contributes to its safety profile by minimizing systemic immune modulation.

Metabolism:
Avacincaptad pegol, as a pegylated RNA aptamer-like oligonucleotide, undergoes minimal metabolic transformation within ocular tissues. Nucleases present in ocular fluids may partially degrade the oligonucleotide; however, its pegylation enhances stability against enzymatic degradation. Systemically, any absorbed avacincaptad pegol would likely be subject to nuclease-mediated catabolism, resulting in oligonucleotide fragments subsequently eliminated. There is no evidence of hepatic metabolism via cytochrome P450 enzymes, significantly reducing potential for drug-drug interactions common among metabolized drugs.

Elimination:
Elimination primarily occurs through ocular clearance mechanisms, including diffusion through the retina and removal via aqueous humor outflow. The elimination half-life within the vitreous humor balances prolonged drug activity with monthly injection intervals. Systemic elimination for minimal systemic exposure proceeds via renal excretion of oligonucleotide fragments formed after nuclease degradation. Clinical pharmacokinetic data report sustained ocular concentrations over several weeks, supporting the recommended 28-day dosing interval. No accumulation in ocular tissues leading to toxicity has been reported in clinical trials.

Dosage Forms

Available Dosage Forms:
- Intravitreal injection solution at a concentration of 20 mg/mL.
- Provided as a single-dose vial containing 2 mg (0.1 mL) of avacincaptad pegol per vial.

Dosages for Adults and Adolescents:
- The recommended dosing regimen for adults with geographic atrophy secondary to AMD is 2 mg administered once monthly via intravitreal injection.
- The injection is given every 28 ± 7 days.
- Prior to injection, intraocular pressure (IOP) assessment is standard, with ocular hypotensive medications administered if necessary to mitigate IOP spikes.

Specific Patient Populations:
- Use in pediatric populations is not established; the drug is currently indicated for adults aged 50 years and older, reflecting the epidemiology of AMD.
- No adjustment of dosage is recommended based on renal or hepatic impairment given localized intravitreal administration and minimal systemic exposure.
- Use in pregnant or breastfeeding women should be approached with caution; discuss potential risks and benefits with the treating physician.
- Patients with active ocular or periocular infections, or active intraocular inflammation, should not receive Izervay.

Clinical administration considerations:
- Prior to administration, the unopened vial may be kept at room temperature (20°C to 25°C) for up to 24 hours.
- The vial must be protected from light, stored refrigerated between 2°C to 8°C, and should not be frozen or shaken.
- Injection must be administered by a qualified healthcare professional trained in intravitreal injections, under sterile conditions.
- Post-injection monitoring of intraocular pressure and ocular inflammation is essential to manage potential adverse effects.

Mechanism Of Action

Izervay’s active component, avacincaptad pegol, is a pegylated RNA aptamer designed as a selective inhibitor of complement component C5, a crucial protein in the complement cascade implicated in pathologic immune activation within the retinal environment. The complement system, part of the innate immune response, when overactivated, causes inflammation and cellular damage in retinal cells, which is a key pathogenic driver of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

By binding with high affinity to the C5 protein, avacincaptad pegol prevents the cleavage of C5 into C5a and C5b fragments, thus blocking downstream formation of the membrane attack complex (MAC) and reducing recruitment of inflammatory cells through C5a-mediated chemotaxis. This targeted inhibition modulates local complement-mediated inflammation, thereby protecting retinal pigment epithelial cells and photoreceptors from complement-induced lysis and apoptosis.

Cellular pathways affected include suppression of the terminal complement pathway, diminishing complement-mediated cytotoxicity and chronic inflammation that contribute to progressive retinal degeneration. Izervay's localized intravitreal administration ensures high drug levels at the disease site, reducing systemic complement interference and potential immunosuppression. This mechanism differentiates Izervay from broad-spectrum immunosuppressants by its precision targeting within the ocular complement cascade.

Clinical studies such as the GATHER1 and GATHER2 Phase 3 trials provide evidence that inhibition of C5 by avacincaptad pegol slows GA lesion growth and vision loss over time compared to placebo. This therapeutic paradigm reflects a breakthrough in AMD management by halting progression rather than only managing symptoms. Compared to other complement inhibitors like pegcetacoplan (which targets C3), Izervay's mechanism at C5 offers a distinct balance of efficacy and safety by preserving upstream complement functions while inhibiting downstream pathologic activation.

Pharmacological Actions

Selective inhibition of complement component C5 protein in the complement cascade.
Reduction of complement-mediated inflammation and cytotoxicity in retinal tissues.
Prevention of membrane attack complex (MAC) formation, protecting retinal pigment epithelial cells.
Modulation of innate immune activation specifically within ocular tissues, minimizing systemic immune suppression.
Neuroprotection of photoreceptors and retinal cells by reducing complement-induced damage.
Slowing progression of geographic atrophy lesions through targeted immune modulation.
Demonstrated efficacy in reducing GA lesion growth rate in clinical trials.
Intravitreal delivery ensuring localized drug effect with minimal systemic exposure.
Maintenance of visual function by delaying retinal degeneration.
Potential to reduce downstream complications related to neovascular AMD progression.
Reduction in retinal inflammation that contributes to vision loss in AMD.

Therapeutic Or Clinical Uses

Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Slowing the progression of retinal lesion enlargement in GA.
Delaying irreversible vision loss associated with advanced dry AMD.
Preserving central vision function for longer durations in affected patients.
Management of chronic complement-mediated retinal degeneration.
First FDA-approved therapy targeting complement C5 in ocular disease.
Adjunct therapy for patients unsuitable for anti-VEGF therapies focusing on wet AMD.
Potential use in slowing GA progression where no other approved treatments previously existed.
Improvement in quality of life by preserving vision-related activities.
Use in adult patients aged 50 years and older with documented GA lesions.
Treatment administered under retinal specialist care via intravitreal injections.

Side Or Adverse Effects

Increased intraocular pressure (reported in approximately 9% of patients).
Blurred vision following intravitreal injections (8% incidence).
Conjunctival hemorrhage presenting as bleeding in the white of the eye (13%).
Choroidal neovascularization (CNV), a potential complication occurring in 7% of patients.
Eye pain post-injection, typically mild and transient (4%).
Vitreous floaters perceived visually by patients (2%).
Blepharitis or inflammation of the eyelids (2%).
Signs of ocular infection such as swelling, crusting, severe pain—require immediate medical attention.
Severe eye redness and increased sensitivity to light noted in some cases.
Visual disturbances including flashes or cloudy vision reported in rare instances.
Risk of endophthalmitis following intravitreal injection procedures.
Potential for retinal detachment as a procedural complication.
Transient discomfort and pressure sensations during injection administration.
Possibility of increased intraocular inflammation necessitating close monitoring.
Rare allergic reactions in patients hypersensitive to avacincaptad pegol or formulation components.

Precautions

Do not administer in presence of active ocular or periocular infections.
Avoid use if patient has active intraocular inflammation.
Monitor intraocular pressure before and after injection to detect pressure spikes.
Use caution when administering in patients with history of retinal detachment or vitreoretinal disorders.
Proper aseptic technique required to reduce risk of endophthalmitis.
Patients should report any sudden vision changes, eye pain, or redness immediately.
Consider withholding treatment in cases of severe eye inflammation or infection.
Avoid driving or operating machinery until visual disturbances resolve post-injection.
Assess patient history for hypersensitivity to components prior to initiating therapy.
Pregnancy and breastfeeding use should be cautiously considered—consult healthcare provider.
Patients with preexisting glaucoma or elevated IOP require careful monitoring.
Coordination with retinal specialists is essential for follow-up and assessment.
Inform patients about potential side effects and signs requiring urgent care.
Ensure proper storage and handling of drug to maintain efficacy and safety.
Evaluate for potential interactions with concomitant ocular medications during treatment.

Warnings

Risk of endophthalmitis associated with intravitreal injection procedures.
Possibility of retinal detachment following ocular injection—patients must be monitored.
Increase in intraocular pressure may occur; vigilant IOP monitoring is critical.
Not for use in patients with ocular or periocular infections.
Use caution in patients with neovascular AMD as disease progression may vary.
Avoid use in presence of active intraocular inflammation to prevent exacerbations.
Potential for serious ocular adverse reactions including severe pain, redness, or vision loss.
Immediate medical evaluation required if signs of infection or severe inflammation develop.
Do not use in patients allergic to avacincaptad pegol or formulation components.
Potential transient visual disturbances post-injection impacting patient safety.
Storage and handling warnings to prevent drug degradation: do not freeze or shake.
Ensure injections are performed by qualified healthcare professionals only.
Patients should be informed about the importance of adherence to monthly dosing schedules.
Careful patient selection is essential to minimize risk of adverse ocular events.
The drug’s safety profile is derived from clinical trials with ongoing post-marketing surveillance.

Contraindication

Known hypersensitivity or allergy to avacincaptad pegol or any excipients in the formulation.
Active ocular or periocular infections, including bacterial, viral, fungal, or other infections.
Presence of active intraocular inflammation such as uveitis or iritis at the time of injection.
Patients with severe ocular conditions that contraindicate intravitreal injections.
Contraindicated in patients unable to tolerate intravitreal injections or with compromised ocular anatomy.
Avoid use in cases of hypersensitivity to pegylated oligonucleotide compounds.
Contraindicated if patient has untreated eye infections due to risk of exacerbation.
Not indicated for use outside of geographic atrophy secondary to age-related macular degeneration.
Patients with uncontrolled glaucoma or severely elevated baseline intraocular pressure where risk outweighs benefit.
Contraindications also extend to improper storage or damaged vials to ensure drug safety.
Avoid use if patient is unable to comply with monthly intravitreal injection regimen due to increased risk.
Contraindicated in patients with active inflammation that could worsen with complement inhibition.
Infection or inflammation at the proposed injection site precludes administration.
Use contraindicated if interferes critically with other ocular treatments needing different management.
Currently no pediatric indication; use contraindicated outside approved adult population.

Drug Interactions

Minimal systemic exposure limits systemic drug interactions with avacincaptad pegol.
Potential additive effects with other intravitreal therapies altering intraocular pressure or inflammation.
Concomitant use of other complement inhibitors has not been systematically studied and may increase immunosuppression.
No known significant cytochrome P450 interactions due to localized ocular administration and lack of liver metabolism.
Avoid simultaneous intravitreal injections of multiple agents at the same visit without clinical justification.
Caution with ocular hypotensive agents as they may be co-administered to manage injection-induced IOP spikes.
Potential interaction with systemic immunosuppressants not established but theoretical immunomodulation present.
Use with anticoagulant ophthalmic agents should be monitored due to increased risk of intraocular hemorrhage.
No evidence of interaction with vitamins or herbal supplements established.
Drug interaction profile is limited due to localized route; however, all medications should be disclosed.
Patients should inform treating physicians of all medications to rule out procedural complications.
Co-administration with anti-VEGF agents needs clinical judgment based on disease state and treatment goals.
No direct antagonistic or synergistic pharmacodynamic interactions documented with current approved ocular drugs.
Potential interactions may arise if systemic infection leads to concomitant systemic complement inhibitory therapy.
Clinical monitoring remains essential whenever initiating or changing concurrent ophthalmic therapies.

Preparations Of The Drug

Avacincaptad pegol formulated as a sterile, preservative-free aqueous solution for intravitreal injection.
Single-dose vials containing 2 mg of avacincaptad pegol in 0.1 mL solution at 20 mg/mL concentration.
Inactive ingredients include dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate, sodium chloride, and water for injection with a pH of approximately 7.3.
The formulation does not contain antimicrobial preservatives; aseptic technique required for preparation and injection.
Stored refrigerated at 2°C to 8°C, protected from light, and must not be frozen or shaken to preserve drug integrity.
Prior to administration, the vial may be equilibrated to room temperature (20°C to 25°C) for up to 24 hours.
The solution is clear to slightly opalescent without visible particulates; inspect visually prior to use.
The pegylated oligonucleotide chemical structure provides stability and extended ocular half-life.
Packaging includes a single-dose glass vial designed to maintain sterility until use.
No diluent or reconstitution required; the drug is ready for intravitreal injection once withdrawn under sterile conditions.
The drug is supplied by Iveric Bio, an Astellas Company, reflecting state-of-the-art manufacturing standards.
J-code J2782 assigned for billing and reimbursement for the intravitreal injection of Izervay.
The medication is specifically formulated for ocular use and is not intended for systemic administration.
Instructions for handling include avoiding light exposure and immediate use after dose preparation.
Patient assistance and financial programs (Izervay My Way) are available to support access and affordability.